In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the Mouse brain and other sites

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 11, 1996, Pages 2632-2636

  Kazragis, Robert J ^a,b,d   Dever, Lisa L ^a,e   Jorgensen, James H ^a   Barbour, Alan G ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MCXI MED ID   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; FOSFOMYCIN; RIFAMPICIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BORRELIA; BORRELIA BURGDORFERI; BORRELIA INFECTION; BRAIN INFECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IMMUNE DEFICIENCY; LYME DISEASE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029910035     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.11.2632     Document Type: Article

References (36)

1. Agger, W. A., S. M. Callister, and D. A. Jobe. 1992. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob. Agents Chemother. 36:1788-1790.
2. Barbour, A. G. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57:71-75.
3. Barbour, A. G., and D. Fish. 1993. The biological and social phenomenon of Lyme disease. Science 260:1610-1616.
4. Barbour, A. G., and S. F. Hayes. 1986. Biology of Borrelia species. Microbiol. Rev. 50:381-400.
5. Barbour, A. G., W. J. Todd, and H. G. Stoenner. 1982. Action of penicillin on Borrelia hermsii. Antimicrob. Agents Chemother. 21:823-829.
6. Barthold, S. W., M. S. de Souza, J. L. Janotka, A. L. Smith, and D. H. Persing. 1993. Chronic Lyme borreliosis in the laboratory mouse. Am. J. Pathol. 143:959-971.
7. Barthold, S. W., C. L. Sidman, and A. L. Smith. 1992. Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunodeficiency. Am. J. Trop. Med. Hyg. 47:605-613.
8. Beskid, G., J. G. Christenson, R. Cleeland, W. DeLorenzo, and P. W. Brown. 1981. In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin. Antimicrob. Agents Chemother. 20:159-167.
9. Cadavid, D., V. Bundoc, and A. G. Barbour. 1993. Experimental infection of the mouse brain by relapsing fever Borrelia species: a molecular analysis. J. Infect. Dis. 168:143-151.
10. Cadavid, D., D. D. Thomas, R. Crawley, and A. G. Barbour. 1994. Variability of a bacterial surface protein and disease expression in a possible mouse model of systemic Lyme borreliosis. J. Exp. Med. 179:631-642.
11. Chapin-Robertson, K., and S. C. Edberg. 1991. Measurement of antibiotics in human body fluids: techniques and significance, p. 295-366. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore.
12. Cooper, G. L., and D. B. Given. 1986. Vancomycin: a comprehensive review of 30 years of clinical experience. Park Row Publishers, Inc., New York.
13. Delaphane, D., R. Yogev, and S. T. Shulman. 1983. Ceftriaxone therapy of group B streptococcal bacteraemia and meningitis in infant rats. J. Antimicrob. Chemother. 11:69-73.
14. Dever, L. L., J. H. Jorgensen, and A. G. Barbour. 1992. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J. Clin. Microbiol. 30:2692-2697.
15. Dever, L. L., J. H. Jorgensen, and A. G. Barbour. 1993. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 37:1115-1121.
16. Ducharme, M. P., R. L. Slaughter, and D. J. Edwards. 1994. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Therapeutic Drug Monitoring 16:513-518.
17. Geraci, J. E., F. R. Heilman, D. R. Nichols, W. E. Wellman, and G. T. Ross. 1956. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Mayo Clin. Proc. 31:564-581.
18. Johnson, R. C. 1989. Isolation techniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. Rev. Infect. Dis. 11(Suppl. 6):S1505-S1510.
19. Johnson, R. C., C. B. Kodner, P. J. Jurkovich, and J. J. Collins. 1990. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob. Agents Chemother. 34:2133-2136.
20. Johnson, R. C., C. Kodner, and M. Russell. 1987. In vitro and in vivo susceptibility of the Lyme disease spirochete Borrelia burgdorferi to four antimicrobial agents. Antimicrob. Agents Chemother. 31:164-167.
21. Lagast, H., P. Dodion, and J. Klastersky. 1986. Comparison of pharmacokinetics and bacterial activity of teicoplanin and vancomycin. J. Antimicrob. Chemother. 18:513-520.
22. Levin, J. M., J. A. Nelson, J. Segreti, B. Harrison, C. A. Benson, and F. Strle. 1993. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents. Antimicrob. Agents Chemother. 37:1444-1446.
23. Moellering, R. C., Jr. 1984. Pharmacokinetics of vancomycin. J. Antimicrob. Chemother. 14(Suppl. D):43-52.
24. Moellering, R. C., Jr., D. C. Yao, and C. Thornsberry. 1991. Approximate concentrations of antimicrobial agents achieved in blood, p. 1201-1202. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
25. Moody, K. D., R. L. Adams, and S. W. Barthold. 1994. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob. Agents Chemother. 38:1567-1572.
26. Mursic, V. P., B. Wilske, G. Schierz, M. Holmburger, and E. Suss. 1987. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur. J. Clin. Microbiol. 6:424-426.
27. Nicolau, D. P., C. D. Freeman, C. H. Nightingale, and R. Quintiliani. 1993. Pharmacokinetics of minocycline and vancomycin in rabbits. Lab. Anim. Sci. 43:222-225.
28. Pachner, A. R., N. Ricalton, and E. Delaney. 1993. Comparison of polymerase chain reaction with culture and serology for diagnosis of murine experimental Lyme borreliosis. J. Clin. Microbiol. 31:208-214.
29. Paster, B. J., F. E. Dewhirst, W. G. Weisberg, L. A. Tordoff, G. J. Fraser, R. B. Hespell, T. B. Stanton, L. Zablen, L. Mandelco, and C. R. Woese. 1991. Phylogenetic analysis of spirochetes. J. Bacteriol. 173:6101-6109.
30. Patel, I. H., S. Chen, M. Parsonnet, M. R. Hackman, M. A. Brooks, J. Konikoff, and S. A. Kaplan. 1981. Pharmacokinetics of ceftriaxone in humans. Antimicrob. Agents Chemother. 20:634-641.
31. Peetermans, W. E., J. J. Hoogeterp, A.-M. Hazekamp-van Dokkum, P. van den Broek, and H. Mattie. 1990. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob. Agents Chemother. 34:1869-1874.
32. Sadziene, A., A. G. Barbour, P. A. Rosa, and D. D. Thomas. 1993. An OspB mutant of Borrelia burgdorferi has reduced invasiveness in vitro and reduced infectivity in vivo. Infect. Immun. 61:3590-3596.
33. Sadziene, A., P. A. Thompson, and A. G. Barbour. 1996. A flagella-less mutant of Borrelia burgdorferi as a live attenuated vaccine in the murine model of Lyme disease. J. Infect. Dis. 173:984-993.
34. Sensible, U. E., S. Gay, C. Museteanu, M. D. Kramer, G. Zimmer, K. Eichmann, U. Museteanu, and M. M. Simon. 1990. Lyme borreliosis in the severe combined immunodeficiency (scid) mouse manifests predominantly in the joints, heart, and liver. Am. J. Pathol. 137:811-820.
35. Sinsky, R. J., and J. Piesman. 1989. Ear punch biopsy method for detection and isolation of Borrelia burgdorferi from rodents. J. Clin. Microbiol. 27: 1723-1727.
36. Steere, A. C. 1989. Lyme disease. N. Engl. J. Med. 321:586-596.